amlodipine has been researched along with Dizziness in 9 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA." | 9.27 | Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018) |
| "The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension." | 9.08 | -Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995) |
| "One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks." | 9.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996) |
| "This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA." | 5.27 | Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018) |
| "The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension." | 5.08 | -Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995) |
| "One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks." | 5.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996) |
| "In a multicentre crossover study of 97 patients with mild hypertension, the incidence and severity of adverse effects were observed during the first 14 days of treatment with amlodipine, nifedipine retard or placebo." | 5.07 | Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. ( Bremner, AD; Fell, PJ; Hosie, J; James, IG; Saul, PA; Taylor, SH, 1993) |
| " Because of interaction between amlodipine and simvastatin, in combination with physical activity, the patient reported: muscle pain, weakness of the muscles, dizziness, and confusion." | 3.81 | [Drug interaction in 63-year-old male sportsman--a case report]. ( Foerster, J; Schetz, D; Sein Anand, J, 2015) |
| "The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine." | 2.69 | Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. ( Aldons, PM; Burgess, ED; Girerd, X; Morgan, TO; Rehn, L; Schaefer, RM; Singh, GP; Tilvis, R, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (77.78) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sung, KC | 1 |
| Oh, YS | 1 |
| Cha, DH | 1 |
| Hong, SJ | 1 |
| Won, KH | 1 |
| Yoo, KD | 1 |
| Rha, SW | 1 |
| Ahn, YK | 1 |
| Ahn, JC | 1 |
| Jang, JY | 1 |
| Hong, TJ | 1 |
| Cho, SK | 1 |
| Park, SH | 1 |
| Hyon, MS | 1 |
| Nam, CW | 1 |
| Chae, IH | 1 |
| Yoo, BS | 1 |
| Song, JM | 1 |
| Jeong, JO | 1 |
| Yoon, YW | 1 |
| Kim, BS | 1 |
| Yang, TH | 1 |
| Cho, DK | 1 |
| Kim, SH | 1 |
| Choi, YJ | 1 |
| Ahn, JH | 1 |
| Jeon, DW | 1 |
| Kim, HS | 1 |
| Schetz, D | 1 |
| Foerster, J | 1 |
| Sein Anand, J | 1 |
| Bremner, AD | 1 |
| Fell, PJ | 1 |
| Hosie, J | 1 |
| James, IG | 1 |
| Saul, PA | 1 |
| Taylor, SH | 1 |
| Kokot, F | 1 |
| Witkowicz, J | 1 |
| Kokot, M | 1 |
| Rychlik, G | 1 |
| Raszewska, J | 1 |
| Corea, L | 1 |
| Cardoni, O | 1 |
| Fogari, R | 1 |
| Innocenti, P | 1 |
| Porcellati, C | 1 |
| Provvidenza, M | 1 |
| Meilenbrock, S | 1 |
| Sullivan, J | 1 |
| Bodin, F | 1 |
| Schaefer, RM | 1 |
| Aldons, PM | 1 |
| Burgess, ED | 1 |
| Tilvis, R | 1 |
| Girerd, X | 1 |
| Singh, GP | 1 |
| Rehn, L | 1 |
| Morgan, TO | 1 |
| Van Der Vring, JA | 3 |
| Daniëls, MC | 3 |
| Holwerda, NJ | 2 |
| Withagen, PJ | 2 |
| Schelling, A | 3 |
| Cleophas, TJ | 3 |
| Hendriks, MG | 3 |
| van der Sluijs, J | 1 |
| Holwerda, KJ | 1 |
| Withagen, AJ | 1 |
| Zwinderman, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by[NCT02738632] | Phase 3 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Completed | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 trials available for amlodipine and Dizziness
1 other study available for amlodipine and Dizziness
| Article | Year |
|---|---|
[Drug interaction in 63-year-old male sportsman--a case report].
Topics: Amlodipine; Confusion; Dizziness; Drug Interactions; Exercise; Humans; Hyperlipidemias; Hypertension | 2015 |